MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab ; volume:12 ; number:1 ; day:6 ; month:5 ; year:2014 ; pages:1-2 ; date:5.2014
Journal of translational medicine ; 12, Heft 1 (6.5.2014), 1-2, 5.2014
- Creator
-
Bifulco, Carlo
- Contributor
-
Capone, Marilena
Feng, Zip
Madonna, Gabriele
Simeone, Ester
Curvietto, Marcello
Mozzillo, Nicola
Ciliberto, Gennaro
Botti, Gerardo
Fox, Bernard A.
Ascierto, Paolo A.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-12-S1-P11
- URN
-
urn:nbn:de:1111-2016041450903
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bifulco, Carlo
- Capone, Marilena
- Feng, Zip
- Madonna, Gabriele
- Simeone, Ester
- Curvietto, Marcello
- Mozzillo, Nicola
- Ciliberto, Gennaro
- Botti, Gerardo
- Fox, Bernard A.
- Ascierto, Paolo A.
- SpringerLink (Online service)
Other Objects (12)
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Melanoma: the role of surgery in the era of new therapies
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Melanoma: A model for testing new agents in combination therapies
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application